苯达莫司汀联合沙利度胺和地塞米松是终末期肾病骨髓瘤患者的有效治疗方法。 - Suppr

Suppr

超能文献

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.

作者信息

Ramasamy Karthik, Hazel Beth, Mahmood Shameem, Corderoy Sophie, Schey Stephen

出版信息

Br J Haematol. 2011 Dec;155(5):632-4. doi: 10.1111/j.1365-2141.2011.08754.x. Epub 2011 Jun 21.

DOI:10.1111/j.1365-2141.2011.08754.x

PMID:21689088

Abstract

摘要

相似文献

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.苯达莫司汀联合沙利度胺和地塞米松是终末期肾病骨髓瘤患者的有效治疗方法。

Br J Haematol. 2011 Dec;155(5):632-4. doi: 10.1111/j.1365-2141.2011.08754.x. Epub 2011 Jun 21.

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.沙利度胺单独或与地塞米松联合用于晚期、复发或难治性多发性骨髓瘤合并肾衰竭患者。

Eur J Haematol. 2004 Aug;73(2):98-103. doi: 10.1111/j.1600-0609.2004.00272.x.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.自体干细胞移植或传统化疗后难治性或复发性多发性骨髓瘤联合使用苯达莫司汀、泼尼松龙和沙利度胺：一项I期临床试验的结果

Br J Haematol. 2008 Oct;143(2):191-200. doi: 10.1111/j.1365-2141.2008.07076.x. Epub 2008 Aug 24.

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.苯达莫司汀、沙利度胺和地塞米松联合治疗复发/难治性骨髓瘤患者：MUKone随机剂量选择试验的结果

Br J Haematol. 2015 Aug;170(3):336-48. doi: 10.1111/bjh.13435. Epub 2015 Apr 20.

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma.苯达莫司汀、沙利度胺和地塞米松是晚期多发性骨髓瘤有效的挽救治疗方案。

Br J Haematol. 2012 Feb;156(4):552-5; author reply 555. doi: 10.1111/j.1365-2141.2011.08887.x. Epub 2011 Sep 26.

Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.克拉霉素联合小剂量地塞米松和沙利度胺是复发/难治性骨髓瘤的有效治疗方法。

Br J Haematol. 2008 Nov;143(3):349-54. doi: 10.1111/j.1365-2141.2008.07360.x. Epub 2008 Aug 28.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.沙利度胺与地塞米松联合治疗新诊断的未接受前期自体干细胞移植的多发性骨髓瘤患者：一项II期试验。

Haematologica. 2005 Dec;90(12):1650-4.

Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.来那度胺、阿霉素和地塞米松联合疗法（RAD）治疗复发/难治性多发性骨髓瘤（MM）的安全性和有效性：单中心经验

Ann Hematol. 2011 Jan;90(1):115-6. doi: 10.1007/s00277-010-0967-4. Epub 2010 Apr 27.

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.沙利度胺-地塞米松作为晚期多发性骨髓瘤的一线治疗方案

Am J Hematol. 2005 Jul;79(3):194-7. doi: 10.1002/ajh.20382.

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.沙利度胺、地塞米松、多柔比星脂质体和硼替佐米（ThaDD-V），随后进行巩固/维持治疗，适用于复发/难治性多发性骨髓瘤患者。

Ann Hematol. 2011 Dec;90(12):1449-56. doi: 10.1007/s00277-011-1217-0. Epub 2011 Mar 25.

引用本文的文献

What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.旧药新用：沙利度胺在多发性骨髓瘤现代治疗中的过去、现在和未来作用。

Target Oncol. 2022 Jul;17(4):383-405. doi: 10.1007/s11523-022-00897-8. Epub 2022 Jun 30.

Current and Novel Alkylators in Multiple Myeloma.多发性骨髓瘤中的当前及新型烷化剂

Cancers (Basel). 2021 May 18;13(10):2465. doi: 10.3390/cancers13102465.

BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.苯达莫司汀：非霍奇金淋巴瘤和慢性淋巴细胞白血病患者新时代的老药

Acta Clin Croat. 2018 Sep;57(3):542-553. doi: 10.20471/acc.2018.57.03.18.

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.苯达莫司汀、泊马度胺和地塞米松用于复发和/或难治性多发性骨髓瘤

Blood Cancer J. 2018 Jul 31;8(8):71. doi: 10.1038/s41408-018-0104-5.

Treatment of relapsed and refractory multiple myeloma.复发难治性多发性骨髓瘤的治疗

Haematologica. 2016 Apr;101(4):396-406. doi: 10.3324/haematol.2015.129189.

European Myeloma Network guidelines for the management of multiple myeloma-related complications.欧洲骨髓瘤网络多发性骨髓瘤相关并发症管理指南。

Haematologica. 2015 Oct;100(10):1254-66. doi: 10.3324/haematol.2014.117176.

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.苯达莫司汀及其代谢产物的药代动力学和药效学特征。

Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54. doi: 10.1007/s00280-015-2727-6. Epub 2015 Apr 1.

Future agents and treatment directions in multiple myeloma.多发性骨髓瘤的未来治疗药物及治疗方向

Expert Rev Hematol. 2014 Feb;7(1):127-41. doi: 10.1586/17474086.2014.858595. Epub 2013 Dec 18.

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).2013 年多发性骨髓瘤的新型药物和新作用机制：国际骨髓瘤工作组（IMWG）的报告。

Leukemia. 2014 Mar;28(3):525-42. doi: 10.1038/leu.2013.350. Epub 2013 Nov 20.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.苯达莫司汀-硼替佐米-地塞米松是一种在复发或难治性多发性骨髓瘤患者中具有活性且耐受性良好的方案。

Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验